Report Detail
Global TCR-Based Antibody Market Research Report 2022
- RnM4438740 |
- 11 May, 2022 |
- Global |
- 97 Pages |
- QYResearch |
- Pharma & Healthcare
Summary:
TCr-Based Antibodies are used in treatment of cancer, lymphoma, myeloma, etc., these antibodies directly attack on the target and kills them.
Industry Insights
Due to the COVID-19 pandemic, the global TCR-Based Antibody market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe TCR-Based Antibody market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe TCR-Based Antibody landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
NY-ESO-1 accounting for % of the TCR-Based Antibody global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of TCR-Based Antibody include Adaptimmune Therapeutics, Celgene, Immunocore, Kuur Therapeutics, Lion TCR, Kite Pharma, Takara Bio, Ziopharm Oncology and GlaxoSmithKline, etc. In terms of revenue, the global 3 largest players have a % market share of TCR-Based Antibody in 2021.
This report focuses on TCR-Based Antibody volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall TCR-Based Antibody market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Post-covid-19 Outlook
The readers in the section will understand how the TCR-Based Antibody market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Segmental Outlook
Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).
Segment by Type
NY-ESO-1
p53
WT-1
EBv
Others
Segment by Application
Hospitals
Specialized Clinics
Pharma and Biotech Research Laboratories.
Gene Therapy Centers
Others
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Competitive Scenario
In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Adaptimmune Therapeutics
Celgene
Immunocore
Kuur Therapeutics
Lion TCR
Kite Pharma
Takara Bio
Ziopharm Oncology
GlaxoSmithKline
Merck
Juno Theraprutics
Frequently Asked Questions
Which product segment grabbed the largest share in the TCR-Based Antibody market?
How is the competitive scenario of the TCR-Based Antibody market?
Which are the key factors aiding the TCR-Based Antibody market growth?
Which are the prominent players in the TCR-Based Antibody market?
Which region holds the maximum share in the TCR-Based Antibody market?
What will be the CAGR of the TCR-Based Antibody market during the forecast period?
Which application segment emerged as the leading segment in the TCR-Based Antibody market?
What key trends are likely to emerge in the TCR-Based Antibody market in the coming years?
What will be the TCR-Based Antibody market size by 2028?
Which company held the largest share in the TCR-Based Antibody market?
Table of Contents
1 TCR-Based Antibody Market Overview
- 1.1 Product Overview and Scope of TCR-Based Antibody
- 1.2 TCR-Based Antibody Segment by Type
- 1.2.1 Global TCR-Based Antibody Sales Growth Rate Comparison by Type (2022-2028)
- 1.2.2 NY-ESO-1
- 1.2.3 p53
- 1.2.4 WT-1
- 1.2.5 EBv
- 1.2.6 Others
- 1.3 TCR-Based Antibody Segment by Application
- 1.3.1 Global TCR-Based Antibody Sales Comparison by Application: (2022-2028)
- 1.3.2 Hospitals
- 1.3.3 Specialized Clinics
- 1.3.4 Pharma and Biotech Research Laboratories.
- 1.3.5 Gene Therapy Centers
- 1.3.6 Others
- 1.4 Global TCR-Based Antibody Market Size Estimates and Forecasts
- 1.4.1 Global TCR-Based Antibody Revenue 2017-2028
- 1.4.2 Global TCR-Based Antibody Sales 2017-2028
- 1.4.3 TCR-Based Antibody Market Size by Region: 2017 Versus 2021 Versus 2028
2 TCR-Based Antibody Market Competition by Manufacturers
- 2.1 Global TCR-Based Antibody Sales Market Share by Manufacturers (2017-2022)
- 2.2 Global TCR-Based Antibody Revenue Market Share by Manufacturers (2017-2022)
- 2.3 Global TCR-Based Antibody Average Price by Manufacturers (2017-2022)
- 2.4 Manufacturers TCR-Based Antibody Manufacturing Sites, Area Served, Product Type
- 2.5 TCR-Based Antibody Market Competitive Situation and Trends
- 2.5.1 TCR-Based Antibody Market Concentration Rate
- 2.5.2 The Global Top 5 and Top 10 Largest TCR-Based Antibody Players Market Share by Revenue
- 2.5.3 Global TCR-Based Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 TCR-Based Antibody Retrospective Market Scenario by Region
- 3.1 Global TCR-Based Antibody Retrospective Market Scenario in Sales by Region: 2017-2022
- 3.2 Global TCR-Based Antibody Retrospective Market Scenario in Revenue by Region: 2017-2022
- 3.3 North America TCR-Based Antibody Market Facts & Figures by Country
- 3.3.1 North America TCR-Based Antibody Sales by Country
- 3.3.2 North America TCR-Based Antibody Revenue by Country
- 3.3.3 United States
- 3.3.4 Canada
- 3.4 Europe TCR-Based Antibody Market Facts & Figures by Country
- 3.4.1 Europe TCR-Based Antibody Sales by Country
- 3.4.2 Europe TCR-Based Antibody Revenue by Country
- 3.4.3 Germany
- 3.4.4 France
- 3.4.5 U.K.
- 3.4.6 Italy
- 3.4.7 Russia
- 3.5 Asia Pacific TCR-Based Antibody Market Facts & Figures by Region
- 3.5.1 Asia Pacific TCR-Based Antibody Sales by Region
- 3.5.2 Asia Pacific TCR-Based Antibody Revenue by Region
- 3.5.3 China
- 3.5.4 Japan
- 3.5.5 South Korea
- 3.5.6 India
- 3.5.7 Australia
- 3.5.8 China Taiwan
- 3.5.9 Indonesia
- 3.5.10 Thailand
- 3.5.11 Malaysia
- 3.6 Latin America TCR-Based Antibody Market Facts & Figures by Country
- 3.6.1 Latin America TCR-Based Antibody Sales by Country
- 3.6.2 Latin America TCR-Based Antibody Revenue by Country
- 3.6.3 Mexico
- 3.6.4 Brazil
- 3.6.5 Argentina
- 3.6.6 Colombia
- 3.7 Middle East and Africa TCR-Based Antibody Market Facts & Figures by Country
- 3.7.1 Middle East and Africa TCR-Based Antibody Sales by Country
- 3.7.2 Middle East and Africa TCR-Based Antibody Revenue by Country
- 3.7.3 Turkey
- 3.7.4 Saudi Arabia
- 3.7.5 UAE
4 Global TCR-Based Antibody Historic Market Analysis by Type
- 4.1 Global TCR-Based Antibody Sales Market Share by Type (2017-2022)
- 4.2 Global TCR-Based Antibody Revenue Market Share by Type (2017-2022)
- 4.3 Global TCR-Based Antibody Price by Type (2017-2022)
5 Global TCR-Based Antibody Historic Market Analysis by Application
- 5.1 Global TCR-Based Antibody Sales Market Share by Application (2017-2022)
- 5.2 Global TCR-Based Antibody Revenue Market Share by Application (2017-2022)
- 5.3 Global TCR-Based Antibody Price by Application (2017-2022)
6 Key Companies Profiled
- 6.1 Adaptimmune Therapeutics
- 6.1.1 Adaptimmune Therapeutics Corporation Information
- 6.1.2 Adaptimmune Therapeutics Description and Business Overview
- 6.1.3 Adaptimmune Therapeutics TCR-Based Antibody Sales, Revenue and Gross Margin (2017-2022)
- 6.1.4 Adaptimmune Therapeutics TCR-Based Antibody Product Portfolio
- 6.1.5 Adaptimmune Therapeutics Recent Developments/Updates
- 6.2 Celgene
- 6.2.1 Celgene Corporation Information
- 6.2.2 Celgene Description and Business Overview
- 6.2.3 Celgene TCR-Based Antibody Sales, Revenue and Gross Margin (2017-2022)
- 6.2.4 Celgene TCR-Based Antibody Product Portfolio
- 6.2.5 Celgene Recent Developments/Updates
- 6.3 Immunocore
- 6.3.1 Immunocore Corporation Information
- 6.3.2 Immunocore Description and Business Overview
- 6.3.3 Immunocore TCR-Based Antibody Sales, Revenue and Gross Margin (2017-2022)
- 6.3.4 Immunocore TCR-Based Antibody Product Portfolio
- 6.3.5 Immunocore Recent Developments/Updates
- 6.4 Kuur Therapeutics
- 6.4.1 Kuur Therapeutics Corporation Information
- 6.4.2 Kuur Therapeutics Description and Business Overview
- 6.4.3 Kuur Therapeutics TCR-Based Antibody Sales, Revenue and Gross Margin (2017-2022)
- 6.4.4 Kuur Therapeutics TCR-Based Antibody Product Portfolio
- 6.4.5 Kuur Therapeutics Recent Developments/Updates
- 6.5 Lion TCR
- 6.5.1 Lion TCR Corporation Information
- 6.5.2 Lion TCR Description and Business Overview
- 6.5.3 Lion TCR TCR-Based Antibody Sales, Revenue and Gross Margin (2017-2022)
- 6.5.4 Lion TCR TCR-Based Antibody Product Portfolio
- 6.5.5 Lion TCR Recent Developments/Updates
- 6.6 Kite Pharma
- 6.6.1 Kite Pharma Corporation Information
- 6.6.2 Kite Pharma Description and Business Overview
- 6.6.3 Kite Pharma TCR-Based Antibody Sales, Revenue and Gross Margin (2017-2022)
- 6.6.4 Kite Pharma TCR-Based Antibody Product Portfolio
- 6.6.5 Kite Pharma Recent Developments/Updates
- 6.7 Takara Bio
- 6.6.1 Takara Bio Corporation Information
- 6.6.2 Takara Bio Description and Business Overview
- 6.6.3 Takara Bio TCR-Based Antibody Sales, Revenue and Gross Margin (2017-2022)
- 6.4.4 Takara Bio TCR-Based Antibody Product Portfolio
- 6.7.5 Takara Bio Recent Developments/Updates
- 6.8 Ziopharm Oncology
- 6.8.1 Ziopharm Oncology Corporation Information
- 6.8.2 Ziopharm Oncology Description and Business Overview
- 6.8.3 Ziopharm Oncology TCR-Based Antibody Sales, Revenue and Gross Margin (2017-2022)
- 6.8.4 Ziopharm Oncology TCR-Based Antibody Product Portfolio
- 6.8.5 Ziopharm Oncology Recent Developments/Updates
- 6.9 GlaxoSmithKline
- 6.9.1 GlaxoSmithKline Corporation Information
- 6.9.2 GlaxoSmithKline Description and Business Overview
- 6.9.3 GlaxoSmithKline TCR-Based Antibody Sales, Revenue and Gross Margin (2017-2022)
- 6.9.4 GlaxoSmithKline TCR-Based Antibody Product Portfolio
- 6.9.5 GlaxoSmithKline Recent Developments/Updates
- 6.10 Merck
- 6.10.1 Merck Corporation Information
- 6.10.2 Merck Description and Business Overview
- 6.10.3 Merck TCR-Based Antibody Sales, Revenue and Gross Margin (2017-2022)
- 6.10.4 Merck TCR-Based Antibody Product Portfolio
- 6.10.5 Merck Recent Developments/Updates
- 6.11 Juno Theraprutics
- 6.11.1 Juno Theraprutics Corporation Information
- 6.11.2 Juno Theraprutics TCR-Based Antibody Description and Business Overview
- 6.11.3 Juno Theraprutics TCR-Based Antibody Sales, Revenue and Gross Margin (2017-2022)
- 6.11.4 Juno Theraprutics TCR-Based Antibody Product Portfolio
- 6.11.5 Juno Theraprutics Recent Developments/Updates
7 TCR-Based Antibody Manufacturing Cost Analysis
- 7.1 TCR-Based Antibody Key Raw Materials Analysis
- 7.1.1 Key Raw Materials
- 7.1.2 Key Suppliers of Raw Materials
- 7.2 Proportion of Manufacturing Cost Structure
- 7.3 Manufacturing Process Analysis of TCR-Based Antibody
- 7.4 TCR-Based Antibody Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
- 8.1 Marketing Channel
- 8.2 TCR-Based Antibody Distributors List
- 8.3 TCR-Based Antibody Customers
9 TCR-Based Antibody Market Dynamics
- 9.1 TCR-Based Antibody Industry Trends
- 9.2 TCR-Based Antibody Market Drivers
- 9.3 TCR-Based Antibody Market Challenges
- 9.4 TCR-Based Antibody Market Restraints
10 Global Market Forecast
- 10.1 TCR-Based Antibody Market Estimates and Projections by Type
- 10.1.1 Global Forecasted Sales of TCR-Based Antibody by Type (2023-2028)
- 10.1.2 Global Forecasted Revenue of TCR-Based Antibody by Type (2023-2028)
- 10.2 TCR-Based Antibody Market Estimates and Projections by Application
- 10.2.1 Global Forecasted Sales of TCR-Based Antibody by Application (2023-2028)
- 10.2.2 Global Forecasted Revenue of TCR-Based Antibody by Application (2023-2028)
- 10.3 TCR-Based Antibody Market Estimates and Projections by Region
- 10.3.1 Global Forecasted Sales of TCR-Based Antibody by Region (2023-2028)
- 10.3.2 Global Forecasted Revenue of TCR-Based Antibody by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
- 12.1 Methodology/Research Approach
- 12.1.1 Research Programs/Design
- 12.1.2 Market Size Estimation
- 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
- 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Author List
Summary:
Get latest Market Research Reports on TCR-Based Antibod. Industry analysis & Market Report on TCR-Based Antibod is a syndicated market report, published as Global TCR-Based Antibody Market Research Report 2022. It is complete Research Study and Industry Analysis of TCR-Based Antibod market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
